Scott D. Myers, MBA

Mr. Myers has been a member of the Dynavax board since October 2021. Mr. Myers has worked in the global pharmaceutical and medical technology industries for nearly three decades. Previously, he was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals, Inc., where he led its turnaround and strategic sale to Covis Pharma, S.à.r.l., a pharmaceutical company, in November 2020. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics, Inc., an oncology biotechnology company focused on late-stage bladder cancer, from June 2018 to January 2020, and served as its Chief Executive Officer from September 2018 to January 2020. Mr. Myers led Rainier’s asset sale of vofatamab to Fusion Pharmaceuticals Inc. Prior to Rainier, Mr. Myers served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Mr. Myers is an independent director on the board of directors of Selecta Biosciences, Trillium Therapeutics, Inc. and Harpoon Therapeutics, Inc. Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago.
Chairman of the Board